BRISTOL MYERS SQUIBB CO - FORM 8-K - EX-99.2 - CERTAIN SUPPLEMENTAL INFORMATION

Attached files

file	filename
EX-99.1 - PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED FEBRUARY 6, 2020 - BRISTOL MYERS SQUIBB CO	q42019ex991.htm
8-K - 8-K - BRISTOL MYERS SQUIBB CO	q42019earningsrelease8.htm

Exhibit 99.2

BRISTOL-MYERS SQUIBB COMPANY

QUARTERLY TREND ANALYSIS OF REVENUES

(Unaudited, dollars in millions)



Revenues	2018																					2019																					% Change				FX Impact
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(a)			Year^(a)			Qtr vs. Qtr		YTD vs. YTD		Qtr vs. Qtr		YTD vs. YTD
United States	$	2,778		$	3,230		$	6,008		$	3,235		$	9,243		$	3,343		$	12,586		$	3,449		$	3,667		$	7,116		$	3,472		$	10,588		$	4,754		$	15,342		42	%	22	%	—		—
Europe	1,406			1,408			2,814			1,365			4,179			1,479			5,658			1,480			1,491			2,971			1,445			4,416			1,850			6,266			25	%	11	%	(3	)%	(6	)%
Rest of the World	873			923			1,796			932			2,728			1,005			3,733			874			988			1,862			976			2,838			1,175			4,013			17	%	8	%	(2	)%	(5	)%
Other	136			143			279			159			438			146			584			117			127			244			114			358			166			524			14	%	(10	)%	N/A		N/A
Total	$	5,193		$	5,704		$	10,897		$	5,691		$	16,588		$	5,973		$	22,561		$	5,920		$	6,273		$	12,193		$	6,007		$	18,200		$	7,945		$	26,145		33	%	16	%	(1	)%	(2	)%

% of Revenues	2018																					2019
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(a)			Year^(a)
United States	53.5		%	56.6		%	55.1		%	56.8		%	55.7		%	56.0		%	55.8		%	58.2		%	58.4		%	58.3		%	57.8		%	58.2		%	59.8		%	58.7		%
Europe	27.1		%	24.7		%	25.8		%	24.0		%	25.2		%	24.8		%	25.1		%	25.0		%	23.8		%	24.4		%	24.1		%	24.3		%	23.3		%	24.0		%
Rest of the World	16.8		%	16.2		%	16.5		%	16.4		%	16.5		%	16.8		%	16.5		%	14.8		%	15.8		%	15.3		%	16.2		%	15.6		%	14.8		%	15.3		%
Other	2.6		%	2.5		%	2.6		%	2.8		%	2.6		%	2.4		%	2.6		%	2.0		%	2.0		%	2.0		%	1.9		%	1.9		%	2.1		%	2.0		%
Total	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%	100.0		%


(a)	Includes Celgene product revenues from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

EARNINGS FROM OPERATIONS

(Unaudited, dollars and shares in millions except per share data)



	2018																					2019																					% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(b)			Year^(b)			Qtr vs. Qtr		YTD vs. YTD
Net product sales	$	4,972		$	5,461		$	10,433		$	5,433		$	15,866		$	5,715		$	21,581		$	5,713		$	6,031		$	11,744		$	5,768		$	17,512		$	7,662		$	25,174		34	%	17	%
Alliance and other revenues	221			243			464			258			722			258			980			207			242			449			239			688			283			971			10	%	(1	)%
Total Revenues	5,193			5,704			10,897			5,691			16,588			5,973			22,561			5,920			6,273			12,193			6,007			18,200			7,945			26,145			33	%	16	%

Cost of products sold^(a)	1,564			1,605			3,169			1,628			4,797			1,670			6,467			1,824			1,972			3,796			1,790			5,586			2,492			8,078			49	%	25	%
Marketing, selling and administrative	980			1,131			2,111			1,104			3,215			1,336			4,551			1,006			1,076			2,082			1,055			3,137			1,734			4,871			30	%	7	%
Research and development	1,247			2,432			3,679			1,277			4,956			1,376			6,332			1,348			1,325			2,673			1,378			4,051			2,097			6,148			52	%	(3	)%
Amortization of acquired intangible assets	24			24			48			24			72			25			97			24			24			48			25			73			1,062			1,135			**		**
Other (income)/expense, net	(401		)	(5		)	(406		)	(509		)	(915		)	61			(854		)	(261		)	100			(161		)	410			249			689			938			**		**
Total Expenses	3,414			5,187			8,601			3,524			12,125			4,468			16,593			3,941			4,497			8,438			4,658			13,096			8,074			21,170			81	%	28	%

Earnings/(Loss) Before Income Taxes	1,779			517			2,296			2,167			4,463			1,505			5,968			1,979			1,776			3,755			1,349			5,104			(129		)	4,975			**		(17	)%
Provision for Income Taxes	284			135			419			255			674			347			1,021			264			337			601			(17		)	584			931			1,515			**		48	%
Net Earnings/(Loss)	1,495			382			1,877			1,912			3,789			1,158			4,947			1,715			1,439			3,154			1,366			4,520			(1,060		)	3,460			**		(30	)%
Noncontrolling Interest	9			9			18			11			29			(2		)	27			5			7			12			13			25			(4		)	21			100	%	(22	)%
Net Earnings/(Loss) Attributable to BMS	$	1,486		$	373		$	1,859		$	1,901		$	3,760		$	1,160		$	4,920		$	1,710		$	1,432		$	3,142		$	1,353		$	4,495		$	(1,056	)	$	3,439		**		(30	)%

Diluted Earnings/(Loss) per Common Share*	$	0.91		$	0.23		$	1.13		$	1.16		$	2.30		$	0.71		$	3.01		$	1.04		$	0.87		$	1.92		$	0.83		$	2.75		$	(0.55	)	$	2.01		**		(33	)%
Weighted-Average Common Shares Outstanding - Diluted	1,640			1,636			1,638			1,636			1,637			1,637			1,637			1,637			1,637			1,637			1,634			1,636			1,918			1,712			—		—
Dividends declared per common share	$	0.40		$	0.40		$	0.80		$	0.40		$	1.20		$	0.41		$	1.61		$	0.41		$	0.41		$	0.82		$	0.41		$	1.23		$	0.45		$	1.68		10	%	4	%

	2018																					2019
% of Total Revenues	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(b)			Year^(b)
Gross Margin	69.9		%	71.9		%	70.9		%	71.4		%	71.1		%	72.0		%	71.3		%	69.2		%	68.6		%	68.9		%	70.2		%	69.3		%	68.6		%	69.1		%

Other Ratios
Effective tax rate	16.0		%	26.1		%	18.2		%	11.8		%	15.1		%	23.1		%	17.1		%	13.3		%	19.0		%	16.0		%	(1.3		)%	11.4		%	(721.7		)%	30.5		%

Other (income)/expense, net	2018																					2019																					% Change
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(b)			Year^(b)			Qtr vs. Qtr		YTD vs. YTD
Interest expense	$	46		$	45		$	91		$	44		$	135		$	48		$	183		$	45		$	123		$	168		$	209		$	377		$	279		$	656		**		**
Pension and postretirement	(11		)	(19		)	(30		)	(10		)	(40		)	13			(27		)	44			26			70			1,537			1,607			(8		)	1,599			**		**
Royalties and licensing income	(367		)	(353		)	(720		)	(338		)	(1,058		)	(295		)	(1,353		)	(308		)	(303		)	(611		)	(356		)	(967		)	(393		)	(1,360		)	33	%	1	%
Divestiture (gains)/losses	(45		)	(25		)	(70		)	(108		)	(178		)	—			(178		)	—			8			8			(1,179		)	(1,171		)	3			(1,168		)	N/A		**
Acquisition expenses	—			—			—			—			—			—			—			165			303			468			7			475			182			657			N/A		N/A
Contingent value right	—			—			—			—			—			—			—			—			—			—			—			—			523			523			N/A		N/A
Investment income	(36		)	(38		)	(74		)	(44		)	(118		)	(55		)	(173		)	(56		)	(119		)	(175		)	(173		)	(348		)	(116		)	(464		)	**		**
Integration expenses	—			—			—			—			—			—			—			22			106			128			96			224			191			415			N/A		N/A
Provision for restructuring	20			37			57			45			102			29			131			12			10			22			10			32			269			301			**		**
Equity investment (gains)/losses	(15		)	356			341			(97		)	244			268			512			(175		)	(71		)	(246		)	261			15			(294		)	(279		)	**		**
Litigation and other settlements	—			(1		)	(1		)	11			10			66			76			1			—			1			(1		)	—			77			77			17	%	1	%
Transition and other service fees	(4		)	(1		)	(5		)	—			(5		)	(7		)	(12		)	(2		)	(2		)	(4		)	(7		)	(11		)	(26		)	(37		)	**		**
Intangible asset impairment	64			—			64			—			64			—			64			—			15			15			—			15			—			15			N/A		(77	)%
Equity in net income of affiliates	(24		)	(27		)	(51		)	(22		)	(73		)	(20		)	(93		)	—			—			—			—			—			4			4			**		**
Other	(29		)	21			(8		)	10			2			14			16			(9		)	4			(5		)	6			1			(2		)	(1		)	**		**
Other (income)/expense, net	$	(401	)	$	(5	)	$	(406	)	$	(509	)	$	(915	)	$	61		$	(854	)	$	(261	)	$	100		$	(161	)	$	410		$	249		$	689		$	938		**		**


*	Quarterly amounts may not add to the year-to-date amounts, as each period is computed on a discrete basis.


**	In excess of +/- 100%.


(a)	Excludes amortization of acquired intangible assets.


(b)	Includes Celgene results of operations from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT

FOR THE PERIOD ENDED DECEMBER 31, 2019

(Unaudited, dollars in millions)



QUARTER-TO-DATE	2019^(b)			2018			$ Change			% Change		Favorable/(Unfavorable) FX Impact $*			2019 Excluding FX		Favorable/(Unfavorable) FX Impact %*		% Change Excluding FX
Revenues	$	7,945		$	5,973		$	1,972		33	%	$	(58	)	$	8,003	(1	)%	34	%
Gross profit	5,453			4,303			1,150			27	%	N/A			N/A		N/A		N/A
Gross profit excluding specified items^(a)	6,138			4,321			1,817			42	%	N/A			N/A		N/A		N/A

Gross profit excluding specified items as a % of revenues	77.3		%	72.3		%

Marketing, selling and administrative	1,734			1,336			398			30	%	11			1,745		1	%	31	%
Marketing, selling and administrative excluding specified items^(a)	1,699			1,335			364			27	%	11			1,710		1	%	28	%

Marketing, selling and administrative excluding specified items as a % of revenues	21.4		%	22.4		%

Research and development	2,097			1,376			721			52	%	3			2,100		1	%	53	%
Research and development excluding specified items^(a)	1,955			1,354			601			44	%	3			1,958		1	%	45	%

Research and development excluding specified items as a % of revenues	24.6		%	22.7		%

YEAR-TO-DATE	2019^(b)			2018			$ Change			% Change		Favorable/(Unfavorable) FX Impact $*			2019 Excluding FX		Favorable/(Unfavorable) FX Impact %*		% Change Excluding FX
Revenues	$	26,145		$	22,561		$	3,584		16	%	$	(492	)	$	26,637	(2	)%	18	%
Gross profit	18,067			16,094			1,973			12	%	N/A			N/A		N/A		N/A
Gross profit excluding specified items^(a)	18,925			16,152			2,773			17	%	N/A			N/A		N/A		N/A

Gross profit excluding specified items as a % of revenues	72.4		%	71.6		%

Marketing, selling and administrative	4,871			4,551			320			7	%	90			4,961		2	%	9	%
Marketing, selling and administrative excluding specified items^(a)	4,835			4,549			286			6	%	90			4,925		2	%	8	%

Marketing, selling and administrative excluding specified items as a % of revenues	18.5		%	20.2		%

Research and development	6,148			6,332			(184		)	(3	)%	31			6,179		1	%	(2	)%
Research and development excluding specified items^(a)	5,891			5,118			773			15	%	31			5,922		1	%	16	%

Research and development excluding specified items as a % of revenues	22.5		%	22.7		%


*	Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales and expenses.


(a)	Refer to the Specified Items schedule for further details.


(b)	Includes Celgene results of operations from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2018														2019														$ Change						% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr^(b)		Year^(b)		Qtr vs. Qtr			YTD vs. YTD			Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Revlimid	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	1,299	$	1,299	$	1,299		$	1,299		N/A		N/A
Eliquis	1,506		1,650		3,156		1,577		4,733		1,705		6,438		1,925		2,042		3,967		1,928		5,895		2,034		7,929		329			1,491			19	%	23	%
Opdivo	1,511		1,627		3,138		1,793		4,931		1,804		6,735		1,801		1,823		3,624		1,817		5,441		1,763		7,204		(41		)	469			(2	)%	7	%
Orencia	593		711		1,304		675		1,979		731		2,710		640		778		1,418		767		2,185		792		2,977		61			267			8	%	10	%
Pomalyst/Imnovid	—		—		—		—		—		—		—		—		—		—		—		—		322		322		322			322			N/A		N/A
Sprycel	438		535		973		491		1,464		536		2,000		459		544		1,003		558		1,561		549		2,110		13			110			2	%	6	%
Yervoy	249		315		564		382		946		384		1,330		384		367		751		353		1,104		385		1,489		1			159			—		12	%
Abraxane	—		—		—		—		—		—		—		—		—		—		—		—		166		166		166			166			N/A		N/A
Empliciti	55		64		119		59		178		69		247		83		91		174		89		263		94		357		25			110			36	%	45	%
Inrebic	—		—		—		—		—		—		—		—		—		—		—		—		5		5		5			5			N/A		N/A

Established Brands
Baraclude	225		179		404		175		579		165		744		141		147		288		145		433		122		555		(43		)	(189		)	(26	)%	(25	)%
Vidaza	—		—		—		—		—		—		—		—		—		—		—		—		58		58		58			58			N/A		N/A
Other Brands^(a)	616		623		1,239		539		1,778		579		2,357		487		481		968		350		1,318		356		1,674		(223		)	(683		)	(39	)%	(29	)%

Total	$	5,193	$	5,704	$	10,897	$	5,691	$	16,588	$	5,973	$	22,561	$	5,920	$	6,273	$	12,193	$	6,007	$	18,200	$	7,945	$	26,145	$	1,972		$	3,584		33	%	16	%


(a)	Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, over-the-counter (OTC) brands and royalty revenue. Other Brands includes $37 million relating to Celgene products from November 20, 2019 through December 31, 2019.


(b)	Includes Celgene product revenues from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE PRO FORMA REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2018														2019														$ Change						% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr^(e)		Year		Qtr vs. Qtr			YTD vs. YTD			Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Revlimid^(a)	$	2,251	$	2,460	$	4,711	$	2,443	$	7,154	$	2,537	$	9,691	$	2,562	$	2,718	$	5,280	$	2,758	$	8,038	$	2,785	$	10,823	$	248		$	1,132		10	%	12	%
Eliquis	1,506		1,650		3,156		1,577		4,733		1,705		6,438		1,925		2,042		3,967		1,928		5,895		2,034		7,929		329			1,491			19	%	23	%
Opdivo	1,511		1,627		3,138		1,793		4,931		1,804		6,735		1,801		1,823		3,624		1,817		5,441		1,763		7,204		(41		)	469			(2	)%	7	%
Orencia	593		711		1,304		675		1,979		731		2,710		640		778		1,418		767		2,185		792		2,977		61			267			8	%	10	%
Pomalyst/Imnovid^(a)	456		508		964		512		1,476		564		2,040		554		617		1,171		662		1,833		692		2,525		128			485			23	%	24	%
Sprycel	438		535		973		491		1,464		536		2,000		459		544		1,003		558		1,561		549		2,110		13			110			2	%	6	%
Yervoy	249		315		564		382		946		384		1,330		384		367		751		353		1,104		385		1,489		1			159			—		12	%
Abraxane^(a)	264		244		508		287		795		268		1,063		285		314		599		317		916		336		1,252		68			189			25	%	18	%
Empliciti	55		64		119		59		178		69		247		83		91		174		89		263		94		357		25			110			36	%	45	%
Inrebic^(b)	—		—		—		—		—		—		—		—		—		—		2		2		9		11		9			11			N/A		N/A

Established Brands
Baraclude	225		179		404		175		579		165		744		141		147		288		145		433		122		555		(43		)	(189		)	(26	)%	(25	)%
Vidaza^(a)	160		163		323		138		461		135		596		148		162		310		146		456		149		605		14			9			10	%	2	%
Other Brands^(c)	695		698		1,393		610		2,003		646		2,649		552		557		1,109		420		1,529		393		1,922		(253		)	(727		)	(39	)%	(27	)%

Total^(d)	$	8,403	$	9,154	$	17,557	$	9,142	$	26,699	$	9,544	$	36,243	$	9,534	$	10,160	$	19,694	$	9,962	$	29,656	$	10,103	$	39,759	$	559		$	3,516		6	%	10	%


(a)	Products were acquired as part of the Celgene acquisition. Reflects product revenues for the period prior to November 20, 2019, which was the date of the acquisition. All product revenues prior to November 20, 2019 have been recast to exclude foreign currency hedge gains and losses.


(b)	Product was acquired as part of the Celgene acquisition. Reflects product revenues for the period prior to November 20, 2019, which was the date of the acquisition.


(c)	Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, OTC brands and royalty revenue. Reflects Celgene product revenues for the period prior to November 20, 2019, which was the date of the acquisition, for such Celgene products.


(d)	All historically reported Celgene revenues have been recast to exclude Otezla^® product revenues.


(e)	Celgene product revenues for the period October 1, 2019 through November 19, 2019 is included below:



Revlimid	$	1,486
Pomalyst/Imnovid	370
Abraxane	170
Inrebic	4
Vidaza	91
Other Brands	37
Total	$	2,158

BRISTOL-MYERS SQUIBB COMPANY

U.S. REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2018														2019														% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr^(c)		Year^(c)		Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Revlimid	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	899	$	899	N/A		N/A
Eliquis	885		979		1,864		917		2,781		979		3,760		1,206		1,269		2,475		1,124		3,599		1,156		4,755		18	%	26	%
Opdivo	938		1,024		1,962		1,141		3,103		1,136		4,239		1,124		1,112		2,236		1,088		3,324		1,020		4,344		(10	)%	2	%
Orencia	385		501		886		474		1,360		515		1,875		449		566		1,015		554		1,569		577		2,146		12	%	14	%
Pomalyst/Imnovid	—		—		—		—		—		—		—		—		—		—		—		—		226		226		N/A		N/A
Sprycel	214		310		524		267		791		300		1,091		240		307		547		325		872		319		1,191		6	%	9	%
Yervoy	162		228		390		278		668		273		941		275		253		528		222		750		254		1,004		(7	)%	7	%
Abraxane	—		—		—		—		—		—		—		—		—		—		—		—		122		122		N/A		N/A
Empliciti	37		41		78		41		119		45		164		58		63		121		62		183		63		246		40	%	50	%
Inrebic	—		—		—		—		—		—		—		—		—		—		—		—		5		5		N/A		N/A

Established Brands
Baraclude	10		9		19		6		25		7		32		7		7		14		2		16		4		20		(43	)%	(38	)%
Vidaza	—		—		—		—		—		—		—		—		—		—		—		—		1		1		N/A		N/A
Other Brands^(a)	147		138		285		111		396		88		484		90		90		180		95		275		108		383		23	%	(21	)%

Total^(b)	$	2,778	$	3,230	$	6,008	$	3,235	$	9,243	$	3,343	$	12,586	$	3,449	$	3,667	$	7,116	$	3,472	$	10,588	$	4,754	$	15,342	42	%	22	%


(a)	Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, OTC brands and royalty revenue. Other Brands includes $27 million relating to Celgene products from November 20, 2019 through December 31, 2019.


(b)	Includes United States and Puerto Rico.


(c)	Includes Celgene product revenues from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

U.S. PRO FORMA REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2018														2019														% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr^(d)		Year		Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Revlimid^(a)	$	1,487	$	1,586	$	3,073	$	1,666	$	4,739	$	1,730	$	6,469	$	1,686	$	1,810	$	3,496	$	1,902	$	5,398	$	1,914	$	7,312	11	%	13	%
Eliquis	885		979		1,864		917		2,781		979		3,760		1,206		1,269		2,475		1,124		3,599		1,156		4,755		18	%	26	%
Opdivo	938		1,024		1,962		1,141		3,103		1,136		4,239		1,124		1,112		2,236		1,088		3,324		1,020		4,344		(10	)%	2	%
Orencia	385		501		886		474		1,360		515		1,875		449		566		1,015		554		1,569		577		2,146		12	%	14	%
Pomalyst/Imnovid^(a)	300		341		641		357		998		393		1,391		390		447		837		469		1,306		489		1,795		24	%	29	%
Sprycel	214		310		524		267		791		300		1,091		240		307		547		325		872		319		1,191		6	%	9	%
Yervoy	162		228		390		278		668		273		941		275		253		528		222		750		254		1,004		(7	)%	7	%
Abraxane^(a)	159		153		312		174		486		177		663		196		207		403		206		609		237		846		34	%	28	%
Empliciti	37		41		78		41		119		45		164		58		63		121		62		183		63		246		40	%	50	%
Inrebic^(a)	—		—		—		—		—		—		—		—		—		—		2		2		9		11		N/A		N/A

Established Brands
Baraclude	10		9		19		6		25		7		32		7		7		14		2		16		4		20		(43	)%	(38	)%
Vidaza^(a)	2		3		5		2		7		2		9		3		3		6		2		8		2		10		—		11	%
Other Brands^(b)	204		190		394		164		558		138		696		135		145		280		147		427		136		563		(1	)%	(19	)%

Total^(c)	$	4,783	$	5,365	$	10,148	$	5,487	$	15,635	$	5,695	$	21,330	$	5,769	$	6,189	$	11,958	$	6,105	$	18,063	$	6,180	$	24,243	9	%	14	%


(a)	Products were acquired as part of the Celgene acquisition. Reflects product revenues for the period prior to November 20, 2019, which was the date of the acquisition.


(b)	Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, OTC brands and royalty revenue. Reflects Celgene product revenues for the period prior to November 20, 2019, which was the date of the acquisition, for such Celgene products.


(c)	Includes United States and Puerto Rico. All historically reported Celgene revenues have been recast to exclude Otezla^® product revenues.


(d)	Celgene product revenues for the period October 1, 2019 through November 19, 2019 is included below:



Revlimid	$	1,015
Pomalyst/Imnovid	263
Abraxane	115
Inrebic	4
Vidaza	1
Other Brands	28
Total	$	1,426

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2018														2019															% Change^(c)
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr			9 Months		4th Qtr^(b)		Year^(b)		Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Revlimid	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—	$	—		$	—	$	400	$	400	N/A		N/A
Eliquis	621		671		1,292		660		1,952		726		2,678		719		773		1,492		804			2,296		878		3,174		21	%	19	%
Opdivo	573		603		1,176		652		1,828		668		2,496		677		711		1,388		729			2,117		743		2,860		11	%	15	%
Orencia	208		210		418		201		619		216		835		191		212		403		213			616		215		831		—		—
Pomalyst/Imnovid	—		—		—		—		—		—		—		—		—		—		—			—		96		96		N/A		N/A
Sprycel	224		225		449		224		673		236		909		219		237		456		233			689		230		919		(3	)%	1	%
Yervoy	87		87		174		104		278		111		389		109		114		223		131			354		131		485		18	%	25	%
Abraxane	—		—		—		—		—		—		—		—		—		—		—			—		44		44		N/A		N/A
Empliciti	18		23		41		18		59		24		83		25		28		53		27			80		31		111		29	%	34	%

Established Brands
Baraclude	215		170		385		169		554		158		712		134		140		274		143			417		118		535		(25	)%	(25	)%
Vidaza	—		—		—		—		—		—		—		—		—		—		—			—		57		57		N/A		N/A
Other Brands^(a)	469		485		954		428		1,382		491		1,873		397		391		788		255		1,043	1,043		248		1,291		(49	)%	(31	)%

Total	$	2,415	$	2,474	$	4,889	$	2,456	$	7,345	$	2,630	$	9,975	$	2,471	$	2,606	$	5,077	$	2,535		$	7,612	$	3,191	$	10,803	21	%	8	%


(a)	Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, OTC brands and royalty revenue. Other Brands includes $10 million relating to Celgene products from November 20, 2019 through December 31, 2019.


(b)	Includes Celgene product revenues from November 20, 2019 through December 31, 2019.


(c)	The foreign exchange impact on international revenues was unfavorable 2% for the fourth quarter and unfavorable 5% year-to-date. The foreign exchange impact on Prioritized Brands is included below.



	Quarter-to-Date						Year-to-Date
	Revenue Change %		Favorable/ (Unfavorable) FX Impact %		Revenue Change % Excluding FX		Revenue Change %		Favorable/ (Unfavorable) FX Impact %		Revenue Change % Excluding FX
Eliquis	21	%	(2	)%	23	%	19	%	(5	)%	24	%
Opdivo	11	%	(4	)%	15	%	15	%	(7	)%	22	%
Orencia	—		(2	)%	2	%	—		(5	)%	5	%
Sprycel	(3	)%	—		(3	)%	1	%	(3	)%	4	%
Yervoy	18	%	(3	)%	21	%	25	%	(6	)%	31	%
Empliciti	29	%	—		29	%	34	%	(2	)%	36	%

BRISTOL-MYERS SQUIBB COMPANY

INTERNATIONAL PRO FORMA REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)



	2018														2019														% Change
	1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr		Year		1st Qtr		2nd Qtr		6 Months		3rd Qtr		9 Months		4th Qtr^(d)		Year		Qtr vs. Qtr		YTD vs. YTD
Prioritized Brands
Revlimid^(a)	$	764	$	874	$	1,638	$	777	$	2,415	$	807	$	3,222	$	876	$	908	$	1,784	$	856	$	2,640	$	871	$	3,511	8	%	9	%
Eliquis	621		671		1,292		660		1,952		726		2,678		719		773		1,492		804		2,296		878		3,174		21	%	19	%
Opdivo	573		603		1,176		652		1,828		668		2,496		677		711		1,388		729		2,117		743		2,860		11	%	15	%
Orencia	208		210		418		201		619		216		835		191		212		403		213		616		215		831		—		—
Pomalyst/Imnovid^(a)	156		167		323		155		478		171		649		164		170		334		193		527		203		730		19	%	12	%
Sprycel	224		225		449		224		673		236		909		219		237		456		233		689		230		919		(3	)%	1	%
Yervoy	87		87		174		104		278		111		389		109		114		223		131		354		131		485		18	%	25	%
Abraxane^(a)	105		91		196		113		309		91		400		89		107		196		111		307		99		406		9	%	2	%
Empliciti	18		23		41		18		59		24		83		25		28		53		27		80		31		111		29	%	34	%

Established Brands
Baraclude	215		170		385		169		554		158		712		134		140		274		143		417		118		535		(25	)%	(25	)%
Vidaza^(a)	158		160		318		136		454		133		587		145		159		304		144		448		147		595		11	%	1	%
Other Brands^(b)	491		508		999		446		1,445		508		1,953		417		412		829		273		1,102		257		1,359		(49	)%	(30	)%

Total^(c)	$	3,620	$	3,789	$	7,409	$	3,655	$	11,064	$	3,849	$	14,913	$	3,765	$	3,971	$	7,736	$	3,857	$	11,593	$	3,923	$	15,516	2	%	4	%


(a)	Products were acquired as part of the Celgene acquisition. Reflects product revenues for the period prior to November 20, 2019, which was the date of the acquisition. All product revenues prior to November 20, 2019 have been recast to exclude foreign currency hedge gains and losses.


(b)	Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets, OTC brands and royalty revenue. Reflects Celgene product revenues for the period prior to November 20, 2019, which was the date of the acquisition, for such Celgene products.


(c)	All historically reported Celgene revenues have been recast to exclude Otezla^® product revenues.


(d)	Celgene product revenues for the period October 1, 2019 through November 19, 2019 is included below:



Revlimid	$	471
Pomalyst/Imnovid	107
Abraxane	55
Inrebic	—
Vidaza	90
Other Brands	9
Total	$	732

BRISTOL-MYERS SQUIBB COMPANY

SPECIFIED ITEMS

(Unaudited, dollars in millions)



	2018																					2019
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(a)			Year^(a)
Impairment charges	$	10		$	—		$	10		$	—		$	10		$	7		$	17		$	—		$	109		$	109		$	9		$	118		$	8		$	126
Inventory purchase price accounting adjustments	—			—			—			—			—			—			—			—			—			—			—			—			660			660
Employee compensation charges	—			—			—			—			—			—			—			—			—			—			—			—			1			1
Site exit and other costs	3			14			17			13			30			11			41			12			30			42			13			55			16			71
Cost of products sold	13			14			27			13			40			18			58			12			139			151			22			173			685			858

Employee compensation charges	—			—			—			—			—			—			—			—			—			—			—			—			27			27
Site exit and other costs	1			—			1			—			1			1			2			1			—			1			—			1			8			9
Marketing, selling and administrative	1			—			1			—			1			1			2			1			—			1			—			1			35			36

License and asset acquisition charges	60			1,075			1,135			—			1,135			—			1,135			—			25			25			—			25			—			25
IPRD impairments	—			—			—			—			—			—			—			32			—			32			—			32			—			32
Employee compensation charges	—			—			—			—			—			—			—			—			—			—			—			—			33			33
Site exit and other costs	20			19			39			18			57			22			79			19			19			38			20			58			109			167
Research and development	80			1,094			1,174			18			1,192			22			1,214			51			44			95			20			115			142			257

Amortization of acquired intangible assets	—			—			—			—			—			—			—			—			—			—			—			—			1,062			1,062

Interest expense	—			—			—			—			—			—			—			—			83			83			166			249			73			322
Pension and postretirement	31			37			68			27			95			26			121			49			44			93			1,545			1,638			(3		)	1,635
Royalties and licensing income	(50		)	(25		)	(75		)	—			(75		)	—			(75		)	—			—			—			(9		)	(9		)	(15		)	(24		)
Divestiture (gains)/losses	(43		)	(25		)	(68		)	(108		)	(176		)	(1		)	(177		)	—			8			8			(1,179		)	(1,171		)	3			(1,168		)
Acquisition expenses	—			—			—			—			—			—			—			165			303			468			7			475			182			657
Contingent value right	—			—			—			—			—			—			—			—			—			—			—			—			523			523
Investment income	—			—			—			—			—			—			—			—			(54		)	(54		)	(99		)	(153		)	(44		)	(197		)
Integration expenses	—			—			—			—			—			—			—			22			106			128			96			224			191			415
Provision for restructuring	20			37			57			45			102			29			131			12			10			22			10			32			269			301
Equity investment (gains)/losses	(15		)	356			341			(97		)	244			268			512			(175		)	(71		)	(246		)	261			15			(294		)	(279		)
Litigation and other settlements	—			—			—			—			—			70			70			—			—			—			—			—			75			75
Intangible asset impairment	64			—			64			—			64			—			64			—			—			—			—			—			—			—
Other	—			—			—			—			—			—			—			—			—			—			—			—			2			2
Other (income)/expense, net	7			380			387			(133		)	254			392			646			73			429			502			798			1,300			962			2,262

Increase/(decrease) to pretax income	101			1,488			1,589			(102		)	1,487			433			1,920			137			612			749			840			1,589			2,886			4,475

Income taxes on items above	(8		)	(218		)	(226		)	1			(225		)	(43		)	(268		)	(43		)	(105		)	(148		)	(275		)	(423		)	(264		)	(687		)
Income taxes attributed to Otezla^® divestiture	—			—			—			—			—			—			—			—			—			—			—			—			808			808
Income taxes attributed to U.S. tax reform	(32		)	3			(29		)	(20		)	(49		)	(7		)	(56		)	—			—			—			—			—			—			—
Income taxes	(40		)	(215		)	(255		)	(19		)	(274		)	(50		)	(324		)	(43		)	(105		)	(148		)	(275		)	(423		)	544			121

Increase/(decrease) to net earnings	$	61		$	1,273		$	1,334		$	(121	)	$	1,213		$	383		$	1,596		$	94		$	507		$	601		$	565		$	1,166		$	3,430		$	4,596


(a)	Includes Celgene results of operations from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

(Unaudited, dollars in millions)



	2018																					2019
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(b)			Year^(b)
Gross Profit	$	3,629		$	4,099		$	7,728		$	4,063		$	11,791		$	4,303		$	16,094		$	4,096		$	4,301		$	8,397		$	4,217		$	12,614		$	5,453		$	18,067
Specified items^(a)	13			14			27			13			40			18			58			12			139			151			22			173			685			858
Gross profit excluding specified items	3,642			4,113			7,755			4,076			11,831			4,321			16,152			4,108			4,440			8,548			4,239			12,787			6,138			18,925

Marketing, selling and administrative	980			1,131			2,111			1,104			3,215			1,336			4,551			1,006			1,076			2,082			1,055			3,137			1,734			4,871
Specified items^(a)	(1		)	—			(1		)	—			(1		)	(1		)	(2		)	(1		)	—			(1		)	—			(1		)	(35		)	(36		)
Marketing, selling and administrative excluding specified items	979			1,131			2,110			1,104			3,214			1,335			4,549			1,005			1,076			2,081			1,055			3,136			1,699			4,835

Research and development	1,247			2,432			3,679			1,277			4,956			1,376			6,332			1,348			1,325			2,673			1,378			4,051			2,097			6,148
Specified items^(a)	(80		)	(1,094		)	(1,174		)	(18		)	(1,192		)	(22		)	(1,214		)	(51		)	(44		)	(95		)	(20		)	(115		)	(142		)	(257		)
Research and development excluding specified items	1,167			1,338			2,505			1,259			3,764			1,354			5,118			1,297			1,281			2,578			1,358			3,936			1,955			5,891

Amortization of acquired intangible assets	24			24			48			24			72			25			97			24			24			48			25			73			1,062			1,135
Specified items^(a)	—			—			—			—			—			—			—			—			—			—			—			—			(1,062		)	(1,062		)
Amortization of acquired intangible assets excluding specified items	24			24			48			24			72			25			97			24			24			48			25			73			—			73

Other (income)/expense, net	(401		)	(5		)	(406		)	(509		)	(915		)	61			(854		)	(261		)	100			(161		)	410			249			689			938
Specified items^(a)	(7		)	(380		)	(387		)	133			(254		)	(392		)	(646		)	(73		)	(429		)	(502		)	(798		)	(1,300		)	(962		)	(2,262		)
Other (income)/expense, net excluding specified items	(408		)	(385		)	(793		)	(376		)	(1,169		)	(331		)	(1,500		)	(334		)	(329		)	(663		)	(388		)	(1,051		)	(273		)	(1,324		)


(a)	Refer to the Specified Items schedule for further details.


(b)	Includes Celgene results of operations from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

RECONCILIATION OF GAAP TO NON-GAAP EPS

(Unaudited, dollars and shares in millions except per share data)



	2018																					2019
	1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr			Year			1st Qtr			2nd Qtr			6 Months			3rd Qtr			9 Months			4th Qtr^(b)			Year^(b)
Earnings/(loss) before income taxes	$	1,779		$	517		$	2,296		$	2,167		$	4,463		$	1,505		$	5,968		$	1,979		$	1,776		$	3,755		$	1,349		$	5,104		$	(129	)	$	4,975
Specified items^(a)	101			1,488			1,589			(102		)	1,487			433			1,920			137			612			749			840			1,589			2,886			4,475
Earnings before income taxes excluding specified items	1,880			2,005			3,885			2,065			5,950			1,938			7,888			2,116			2,388			4,504			2,189			6,693			2,757			9,450

Provision for income taxes	284			135			419			255			674			347			1,021			264			337			601			(17		)	584			931			1,515
Income taxes on specified items^(a)	8			218			226			(1		)	225			43			268			43			105			148			275			423			264			687
Income taxes attributed to Otezla^® divestiture^(a)	—			—			—			—			—			—			—			—			—			—			—			—			(808		)	(808		)
Income taxes attributed to U.S. tax reform^(a)	32			(3		)	29			20			49			7			56			—			—			—			—			—			—			—
Provision for income taxes excluding tax on specified items and income taxes attributed to U.S. tax reform	324			350			674			274			948			397			1,345			307			442			749			258			1,007			387			1,394

Noncontrolling Interest	9			9			18			11			29			(2		)	27			5			7			12			13			25			(4		)	21
Specified items^(a)	—			—			—			—			—			—			—			—			—			—			—			—			—			—
Noncontrolling Interest excluding specified items	9			9			18			11			29			(2		)	27			5			7			12			13			25			(4		)	21

Net Earnings/(Loss) Attributable to BMS used for Diluted EPS Calculation - GAAP	1,486			373			1,859			1,901			3,760			1,160			4,920			1,710			1,432			3,142			1,353			4,495			(1,056		)	3,439
Specified items^(a)	61			1,273			1,334			(121		)	1,213			383			1,596			94			507			601			565			1,166			3,430			4,596
Net Earnings Attributable to BMS used for Diluted EPS Calculation excluding specified items - Non-GAAP	1,547			1,646			3,193			1,780			4,973			1,543			6,516			1,804			1,939			3,743			1,918			5,661			2,374			8,035

Weighted-average Common Shares Outstanding - Diluted-GAAP	1,640			1,636			1,638			1,636			1,637			1,637			1,637			1,637			1,637			1,637			1,634			1,636			1,918			1,712
Weighted-average Common Shares Outstanding - Diluted-Non-GAAP	1,640			1,636			1,638			1,636			1,637			1,637			1,637			1,637			1,637			1,637			1,634			1,636			1,941			1,712

Diluted Earnings/(Loss) Per Share - GAAP*	$	0.91		$	0.23		$	1.13		$	1.16		$	2.30		$	0.71		$	3.01		$	1.04		$	0.87		$	1.92		$	0.83		$	2.75		$	(0.55	)	$	2.01
Diluted Earnings/(Loss) Per Share Attributable to specified items^(a)	0.03			0.78			0.82			(0.07		)	0.74			0.23			0.97			0.06			0.31			0.37			0.34			0.71			1.77			2.68
Diluted Earnings Per Share - Non-GAAP*	$	0.94		$	1.01		$	1.95		$	1.09		$	3.04		$	0.94		$	3.98		$	1.10		$	1.18		$	2.29		$	1.17		$	3.46		$	1.22		$	4.69

Effective Tax Rate	16.0		%	26.1		%	18.2		%	11.8		%	15.1		%	23.1		%	17.1		%	13.3		%	19.0		%	16.0		%	(1.3		)%	11.4		%	(721.7		)%	30.5		%
Specified items^(a)	1.2		%	(8.6		)%	(0.9		)%	1.5		%	0.8		%	(2.6		)%	—			1.2		%	(0.5		)%	0.6		%	13.1		%	3.6		%	735.7		%	(15.7		)%
Effective Tax Rate excluding specified items	17.2		%	17.5		%	17.3		%	13.3		%	15.9		%	20.5		%	17.1		%	14.5		%	18.5		%	16.6		%	11.8		%	15.0		%	14.0		%	14.8		%


*	Quarterly amounts may not add to the year-to-date amounts, as each period is computed on a discrete basis.


(a)	Refer to the Specified Items schedule for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.


(b)	Includes Celgene results from operations from November 20, 2019 through December 31, 2019.

BRISTOL-MYERS SQUIBB COMPANY

SELECTED BALANCE SHEET INFORMATION

(Unaudited, dollars in millions)



	March 31, 2018			June 30, 2018			September 30, 2018			December 31, 2018			March 31, 2019			June 30, 2019			September 30, 2019			December 31, 2019^(a)
Cash and cash equivalents	$	5,342		$	4,999		$	5,408		$	6,911		$	7,335		$	28,404		$	30,489		$	12,346
Marketable debt securities - current	1,296			940			1,281			1,848			1,429			953			2,053			3,047
Marketable debt securities - non-current	2,252			2,117			2,017			1,775			1,233			994			925			767
Cash, cash equivalents and marketable debt securities	8,890			8,056			8,706			10,534			9,997			30,351			33,467			16,160

Short-term debt obligations	(1,925		)	(1,716		)	(1,620		)	(1,703		)	(381		)	(545		)	(569		)	(3,346		)
Long-term debt	(5,775		)	(5,671		)	(5,687		)	(5,646		)	(5,635		)	(24,433		)	(24,390		)	(43,387		)
Net (debt)/cash position	$	1,190		$	669		$	1,399		$	3,185		$	3,981		$	5,373		$	8,508		$	(30,573	)


(a)	Includes Celgene balances as of December 31, 2019.

Prior period amounts were conformed to current period presentation.

BRISTOL-MYERS SQUIBB COMPANY

2020 FULL YEAR PROJECTED DILUTED EPS FROM OPERATIONS

EXCLUDING PROJECTED SPECIFIED ITEMS



	Full Year 2020
	Pre-tax		Tax		After-tax
Projected Diluted Earnings Attributable to Shareholders per Common Share - GAAP					$0.75 to $0.95

Projected Specified Items:
Purchase price accounting adjustments^(a)	5.21		0.48		4.73
Acquisition, restructuring and integration expenses^(b)	0.46		0.09		0.37
Research and development license and asset acquisition charges	0.15		0.02		0.13
Employee compensation charges^(c)	0.05		0.01		0.04
Divestiture gains and licensing income	(0.03	)	(0.01	)	(0.02	)
Total	5.84		0.59		5.25

Projected Diluted Earnings Attributable to Shareholders per Common Share - Non-GAAP					$6.00 to $6.20


(a)	Includes amortization of acquired intangible assets, unwind of inventory fair value adjustments and amortization of fair value adjustments of debt assumed from Celgene.


(b)	Includes acquisition-related financing, transaction, restructuring and integration expenses recognized in Cost of products sold, Research and development and Other (income)/expense, net.


(c)	Includes items recognized in Cost of products sold, Marketing, selling and administrative and Research and development.



The following table summarizes the company's 2020 financial guidance:

Line item	GAAP	Non-GAAP

Revenues	$40.5 billion - $42.5 billion	$40.5 billion - $42.5 billion

Gross margin as a percent of revenue	Approximately 74%	Approximately 80%

Marketing, selling and administrative expense	$6.8 billion - $7.0 billion	$6.8 billion - $7.0 billion

Research and development expense	$10.1 billion - $10.3 billion	$9.6 billion - $9.8 billion

Other (income)/expense, net	$0.6 billion - $0.7 billion	($0.1 billion) - ($0.2 billion)

Effective tax rate	Approximately 43%	Approximately 17%

Weighted average diluted shares	Approximately 2.3 billion	Approximately 2.3 billion

The GAAP financial results for the full year of 2020 will include specified items, including purchase price accounting adjustments, acquisition and integration expenses, charges associated with restructuring, downsizing and streamlining worldwide operations, research and development license and asset acquisition charges, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards and certain retention-related compensation charges related to the Celgene transaction, pension charges, among other items. The financial guidance for 2020 excludes the impact of any potential future strategic acquisitions and divestitures and other specified items that have not yet been identified and quantified. For a fuller discussion of items that could impact full year GAAP results, as well as the use of non-GAAP financial information, see Bristol-Myers Squibb Reports Fourth Quarter Financial Results on February 6, 2020, including “2020 Financial Guidance” and “Use of non-GAAP Financial Information” therein.

BRISTOL MYERS SQUIBB CO - FORM 8-K - EX-99.2 - CERTAIN SUPPLEMENTAL INFORMATION - February 6, 2020

Attached files

BRISTOL MYERS SQUIBB CO Reports